Gemfibrozil治疗脂蛋白升高患者a:一项初步研究。
文章的细节
-
引用
复制到剪贴板 -
Fereshetian AG, Davidson M, Haber H, Black DM
Gemfibrozil治疗脂蛋白升高患者a:一项初步研究。
临床药物研究，1998;16(1):1-7。doi: 10.2165 / 00044011-199816010-00001。
- PubMed ID
-
18370512 (PubMed视图］
- 摘要
-
目的:本先导研究探讨了大剂量吉斐齐(2400 mg/day)治疗脂蛋白(a)升高患者[Lp(a)]的疗效。Lp(a)已被证明是冠心病(CHD)发展的独立危险因素。患者:11名血清Lp(a) >/=45 mg/dl的患者参与了这项为期12周的研究。最初，所有患者均口服gemfibrozil 600mg，每日2次。每隔4周，对于能够耐受增加的患者，剂量增加600mg，最高可达2400 mg/天。结果:8例患者完成了研究。其中3例患者符合临床意义Lp(a)降低33%的预定标准。Lp(a)的平均百分比变化为-18.3 +/- 15.4%，差异无统计学意义(p = 0.14, 1尾)。所有患者血浆甘油三酯均显著降低。平均百分比变化为-62.5 +/- 1.8% (p < 0.001, 1尾)。 The mean percentage change in total cholesterol was -12.4 +/- 3.8% (p = 0.007, 1-tailed). Gemfibrozil was considered suspect in five of 16 adverse events reported, but only one of these (dyspepsia) caused withdrawal from the study. For all patients participating in the study no adverse event was characterised as severe. CONCLUSION: While the small number of patients does not allow any definitive conclusion on effectiveness to be drawn, the results suggest that further randomised studies utilising larger patient numbers appear warranted.
引用本文的药物库数据
- 药物